NCT02254044View on ClinicalTrials.gov

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2004

Conditions
Carcinoma, Squamous Cell
Interventions
DRUG

bivatuzumab mertansine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02254044 - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus | Biotech Hunter | Biotech Hunter